Regadenoson 400micrograms/5ml solution for injection vials
Requires a prescription from a doctor or prescriber
Regadenoson is an A2A adenosine receptor agonist that causes coronary vasodilation and used for myocardial perfusion imagining.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Regadenoson
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Regadenoson
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Regadenoson on the MHRA register
Rapiscan 400micrograms/5ml solution for injection vials
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 6 · Randomised trials: 4 · 2015–2026
Showing the 50 most relevant studies, sorted by most relevant.
Gregory S. Thomas, S. James Cullom, Therese M. Kitt, et al.
Journal of Nuclear Cardiology, 2017
Blood Advances, 2017
Joshua J. Field, Elaine Majerus, Victor R. Gordeuk, et al.
Blood Advances, 2017
Gkotsis DE, Raiter Y, Thompson D, et al.
2026
Regadenoson is a well-established selective A2A adenosine receptor agonist able to induce coronary vasodilation, thus serving as an effective agent for stress myocardial perfusion imaging with several imaging modalities. Regadenoson is approved to be used in adults, but it is also used off-label in the pediatric setting. This paper summarizes the findings from the published literature on the use of regadenoson in pediatric populations undergoing stress CMR. Publications were identified via literature search on PubMed and Google Scholar and assessed for efficacy, adverse events, imaging-related aspects, use of stress-reversal agents, posology, and use of anesthesia. Nine publications met the criteria for this paper, reporting on a cumulative total of 276 pediatric patients, male and female, age range 2 months - 18 years, evaluated with regadenoson-based stress CMR between 2017 and 2025. Authors of all identified publications were based in the USA. In seven out of nine studies the regadenoson posology was weight-based (6-10 µg/kg). Several different contrast agents were used alongside regadenoson. No serious adverse events (AEs) were reported. All minor AEs reported in the studies were either resolved via stress-reversal agent, or self-resolved by the end of the exam. Using a random effects model that considers both within-study variance and between-study variance, the average heart rate at rest was found to be 81.9 [75.1; 88.7], and at stress 119.6 [114.9; 124.2] (delta = 37.7 bpm). In the United States, regadenoson is being used off-label for stress perfusion CMR in pediatric populations. Published reports indicate that regadenoson is efficacious and well-tolerated in this population.
Abstract licence: CC BY
Muhammad-Nasser A, Seibel G, Riad M, et al.
2026
In this case series and review, we highlight 2 adult congenital cases, diagnosed with anomalous origin of the right coronary artery (RCA) from the pulmonary artery (PA). Patient 1 is a 57-year-old woman who presented to the cardiology clinic for episodes of palpitations and dizziness associated with dyspnea on minimal exertion. Ambulatory electrocardiograph monitoring revealed brief runs of nonsustained ventricular tachycardia and supraventricular tachycardia up to 3 minutes. Cardiac computed tomography angiography revealed anomalous origin of the RCA from the main PA. Nuclear Regadenoson stress test demonstrated anterior wall/anterolateral wall peri-infarctional ischemia. She underwent successful surgical repair with coronary reimplantation. Patient 2 is a 61-year-old man who presented to the emergency department for shortness of breath and alcohol intoxication. Computed tomography angiography of the chest/abdomen/pelvis was performed in the emergency department that was suspicious for anomalous RCA. Left heart catheterization revealed large RCA, with anomalous origin from the PA.
Abstract licence: CC BY
Aiden Abidov, Ahmed Pasha, Arun Kannan, et al.
Journal of the American College of Cardiology, 2015
Aviral Vij, Yasmeen Golzar, Rami Doukky
Journal of Nuclear Cardiology, 2018
Karim O Elkholy, Omar Hegazy, Adeniyi Okunade, et al.
Cureus, 2021
Ambereen Ahmed
Quantitative Phase Imaging IV, 2018
Talal Asif, Katherine Lee Chuy, Saurabh Malhotra
Journal of Nuclear Cardiology, 2021
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
2-4 minutes
Mechanism
Regadenoson is an selective low-affinity (Ki= 1.
Food interactions
1 warning
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
1 to 3 minutes
Half-life
2-4 minutes
Intermediate phase: 30 minutes (this phase coincides with a loss of the pharmacodynamic effect);
Terminal phase:…
Volume of distribution
11.5 L
Steady state: 78.7 L
Metabolism
Elimination
58%
Clearance
450 mL/min
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medicines. Always consult a healthcare professional.
Showing 40 of 40 interactions
MTD (male, supine position): 20 µg/kg;
MTD (male, standing position): 10 µg/kg;
How the body processes this drug — absorption, distribution, metabolism, and elimination
T max, injection = 1 to 3 minutes;
Onset of pharmacodynamic response = 1 to 3 minutes;
E max 12.3 ng/mL
Intermediate phase: 30 minutes (this phase coincides with a loss of the pharmacodynamic effect);
Terminal phase: 2 hours
Steady state: 78.7 L
Proteins and enzymes this drug interacts with in the body
ATC C01EB21
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Regadenoson
Additional database identifiers
ChemSpider
189859
BindingDB
50119132
ZINC
ZINC000013818943
HUGO Gene Nomenclature Committee (HGNC)
HGNC:263
GenAtlas
ADORA2A
GeneCards
ADORA2A
GenBank Gene Database
M97370
GenBank Protein Database
177892
Guide to Pharmacology
19
UniProt Accession
AA2AR_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72